These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases. Knoll J Med Res Rev; 1992 Sep; 12(5):505-24. PubMed ID: 1513186 [TBL] [Abstract][Full Text] [Related]
23. [Medicamentous strategy for improving the quality of life in the senescence]. Knoll J Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965 [TBL] [Abstract][Full Text] [Related]
24. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research. Magyar K; Szende B; Lengyel J; Tekes K J Neural Transm Suppl; 1996; 48():29-43. PubMed ID: 8988460 [TBL] [Abstract][Full Text] [Related]
25. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. Knoll J J Neural Transm Suppl; 1993; 40():69-91. PubMed ID: 8294902 [TBL] [Abstract][Full Text] [Related]
26. Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant. Seif-El-Nasr M; Atia AS; Abdelsalam RM Arzneimittelforschung; 2008; 58(4):160-7. PubMed ID: 18540477 [TBL] [Abstract][Full Text] [Related]
27. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease. Youdim MB; Riederer P Mov Disord; 1993; 8 Suppl 1():S8-13. PubMed ID: 8302308 [TBL] [Abstract][Full Text] [Related]
28. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease? Sandler M J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254 [TBL] [Abstract][Full Text] [Related]
29. Dopamine oxidation and its inhibition by (-)-deprenyl in man. Glover V; Elsworth JD; Sandler M J Neural Transm Suppl; 1980; (16):163-72. PubMed ID: 6776235 [TBL] [Abstract][Full Text] [Related]
30. Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Heikkila RE; Kindt MV; Sonsalla PK; Giovanni A; Youngster SK; McKeown KA; Singer TP Proc Natl Acad Sci U S A; 1988 Aug; 85(16):6172-6. PubMed ID: 3137566 [TBL] [Abstract][Full Text] [Related]
31. The pharmacology of (-)deprenyl. Knoll J J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262 [TBL] [Abstract][Full Text] [Related]
32. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. Engberg G; Elebring T; Nissbrandt H J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311 [TBL] [Abstract][Full Text] [Related]
33. The role of MAO in MPTP toxicity--a review. Glover V; Gibb C; Sandler M J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762 [TBL] [Abstract][Full Text] [Related]
34. A review of the pharmacology of selegiline. Heinonen EH; Lammintausta R Acta Neurol Scand Suppl; 1991; 136():44-59. PubMed ID: 1686954 [TBL] [Abstract][Full Text] [Related]